Target intelligence / Profile preview

U1 spliceosomal RNA (U1 snRNA)

Target
U1 snRNA
Molecular classification
Small nuclear RNA (snRNA), Non-coding RNA, Component of spliceosome, RNA-processing factor, Other
01

Overview

U1 spliceosomal RNA is a small nuclear RNA (snRNA) of 164 nucleotides in humans, serving as a critical part of the U1 small nuclear ribonucleoprotein (snRNP) within the spliceosome, the multi-megadalton complex responsible for pre-mRNA splicing in eukaryotic cells. U1 snRNA recognizes and base-pairs with the 5′ splice site of introns in pre-mRNA, thereby initiating spliceosome assembly. The U1 snRNP further consists of the U1 RNA, core Sm proteins, and U1-specific proteins (U1-70K, U1-A, and U1-C), which collectively mediate splice site recognition and facilitate subsequent splicing reactions. Structural studies have elucidated stem-loop motifs and complex RNA-protein interactions that are evolutionarily conserved. Recent research has revealed additional roles for U1 snRNP in regulation of alternative polyadenylation and transcript processing. Mutations or misregulation of spliceosomal RNA components can lead to aberrant splicing and disease states, including various cancers and neurodegenerative conditions. While not directly used as a biomarker, aberrant splicing activity involving U1 snRNA may serve as a molecular indicator of splicing defects or disease.

Other names
U1 spliceosomal RNAU1 snRNAU1 small nuclear RNAsnRNA U1U1 snRNP RNA component
02

Mechanism of action

N/A. No drugs are known to target this RNA directly; some experimental oligonucleotides (antisense morpholinos) have been used to modulate its activity in research settings, but these are not approved therapies.

03

Biological functions

Pre-mRNA splicingRecognition of 5′ splice site in pre-mRNAAssembly of spliceosomeRegulation of alternative polyadenylationRNA processing
04

Disease associations

Cancer (due to splicing errors and misregulation)Neurodegenerative disease (splicing defects implicated)Other (general RNA splicing-related diseases)
05

Safety considerations

Therapeutic challenge in targeting: Essential for normal cell function—disruption may lead to widespread RNA splicing defects, cell death, or diseaseOff-target effects if modulated therapeutically

Beyond the preview

Go deeper on U1 spliceosomal RNA (U1 snRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on U1 spliceosomal RNA (U1 snRNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call